Scinai Immunotherapeutics Ltd. (SCNI) Soars 55.12% on Positive Publication

Generado por agente de IAAinvest Pre-Market Radar
martes, 29 de julio de 2025, 7:32 am ET1 min de lectura

On July 29, 2025,

Immunotherapeutics Ltd. (SCNI) experienced a significant surge, rising by 55.12% in pre-market trading, indicating a strong bullish sentiment among investors.

Scinai Immunotherapeutics Ltd. recently announced a new peer-reviewed publication, which is likely to have contributed to the positive market sentiment. The company, specializing in inflammation and immunology biological products, has been making strides in the biopharmaceutical sector, which has garnered investor interest.

Additionally, Scinai Immunotherapeutics Ltd. has secured new funding and is expanding its contract development and manufacturing organization (CDMO) capabilities ahead of the BIO 2025 conference. This strategic move is expected to enhance the company's operational efficiency and market presence, further boosting investor confidence.

The company's recent extension to meet Nasdaq's equity and bid price standards has also been well-received by the market, as it provides Scinai with more time to stabilize its financial position and focus on growth initiatives.

author avatar
Ainvest Pre-Market Radar

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios